Index -
P/E -
EPS (ttm) -4.19
Insider Own 15.51%
Shs Outstand 32.02M
Perf Week 5.08%
Market Cap 132.54M
Forward P/E -
EPS next Y -1.28
Insider Trans 3.64%
Shs Float 27.05M
Perf Month 13.11%
Income -108.44M
PEG -
EPS next Q -0.74
Inst Own 10.99%
Short Float 6.42%
Perf Quarter 126.23%
Sales 490.74M
P/S 0.27
EPS this Y 54.97%
Inst Trans -15.03%
Short Ratio 2.35
Perf Half Y 157.14%
Book/sh 6.55
P/B 0.63
EPS next Y 32.16%
ROA -12.77%
Short Interest 1.74M
Perf Year 12.81%
Cash/sh 0.67
P/C 6.18
EPS next 5Y -
ROE -49.33%
52W Range 1.23 - 11.42
Perf YTD 12.81%
Dividend Est. -
P/FCF -
EPS past 5Y -122.90%
ROI -18.06%
52W High -63.74%
Beta 3.60
Dividend TTM -
Quick Ratio 0.91
Sales past 5Y 117.65%
Gross Margin 11.01%
52W Low 237.41%
ATR (14) 0.65
Dividend Ex-Date -
Current Ratio 1.37
EPS Y/Y TTM -2.07%
Oper. Margin -15.54%
RSI (14) 50.14
Volatility 12.57% 16.93%
Employees 2075
Debt/Eq 2.61
Sales Y/Y TTM -14.27%
Profit Margin -22.10%
Recom 1.67
Target Price 6.67
Option/Short Yes / Yes
LT Debt/Eq 2.52
EPS Q/Q -93.55%
Payout -
Rel Volume 0.82
Prev Close 4.22
Sales Surprise 11.53%
EPS Surprise 25.13%
Sales Q/Q -7.33%
Earnings Dec 03 AMC
Avg Volume 739.35K
Price 4.14
SMA20 -8.02%
SMA50 23.47%
SMA200 32.75%
Trades
Volume 606,602
Change -1.90%
Date
Action
Analyst
Rating Change
Price Target Change
May-14-24 Downgrade
Jefferies
Buy → Hold
$11.50 → $3.75
Feb-09-24 Upgrade
Jefferies
Hold → Buy
$3 → $11.50
Jul-20-23 Initiated
Wells Fargo
Overweight
$9
Jan-19-23 Downgrade
Jefferies
Buy → Hold
$10 → $8
Jan-11-23 Upgrade
Lake Street
Hold → Buy
$4 → $10
Nov-18-22 Downgrade
Lake Street
Buy → Hold
$60 → $7
Oct-04-22 Initiated
Jefferies
Buy
$27
Jan-31-22 Initiated
Lake Street
Buy
$60
Sep-20-21 Initiated
Craig Hallum
Buy
$45
Dec-30-24 04:05PM
Dec-23-24 04:05PM
Dec-18-24 08:00AM
Dec-17-24 04:03PM
Dec-04-24 02:00AM
04:05PM
Loading…
Dec-03-24 04:05PM
Dec-02-24 07:02AM
Nov-21-24 08:30AM
Nov-20-24 04:05PM
Nov-07-24 08:00AM
Oct-09-24 05:54PM
Sep-16-24 08:00AM
Aug-28-24 04:05PM
Aug-08-24 06:15PM
04:05PM
08:00AM
Loading…
Jul-25-24 08:00AM
Jul-09-24 06:50AM
Jul-01-24 10:20AM
Jun-10-24 07:30AM
Jun-03-24 02:49PM
(Associated Press Finance) +16.04%
01:24PM
May-23-24 04:15PM
May-15-24 09:54PM
04:05PM
May-14-24 08:19AM
07:34AM
07:00AM
May-10-24 05:20AM
May-09-24 06:56PM
Apr-29-24 04:05PM
08:50AM
Loading…
Apr-03-24 08:50AM
Apr-02-24 08:50AM
Mar-25-24 09:40AM
Mar-18-24 08:50AM
Mar-12-24 04:42PM
Mar-07-24 04:20PM
12:00PM
08:50AM
Mar-01-24 09:40AM
Feb-29-24 08:50AM
Feb-27-24 01:34PM
Feb-20-24 07:38AM
Feb-19-24 08:50AM
Feb-14-24 09:40AM
Feb-09-24 08:25AM
Feb-08-24 09:55AM
08:54AM
(Thomson Reuters StreetEvents)
Feb-07-24 06:10PM
04:05PM
Jan-29-24 04:05PM
Jan-27-24 09:00AM
Dec-16-23 03:01PM
Dec-15-23 08:50AM
Dec-14-23 08:14AM
Dec-12-23 07:45AM
(Thomson Reuters StreetEvents) -15.84%
Dec-11-23 09:54PM
04:05PM
Dec-06-23 04:30PM
Nov-27-23 04:05PM
(GlobeNewswire) -13.73%
+6.12%
Nov-13-23 04:05PM
Nov-08-23 07:30AM
Nov-01-23 08:00AM
Oct-16-23 08:00AM
Aug-29-23 06:47PM
Aug-24-23 04:05PM
Aug-15-23 03:31PM
(The Wall Street Journal) -6.86%
Aug-10-23 06:15PM
04:08PM
Jul-24-23 04:35PM
Jul-20-23 08:24PM
Jun-30-23 08:44AM
Jun-05-23 09:55AM
May-30-23 08:50AM
May-25-23 08:33AM
May-19-23 08:33AM
May-18-23 09:55AM
May-13-23 08:15AM
May-11-23 05:55PM
04:05PM
May-08-23 08:18AM
06:27AM
May-04-23 08:33AM
Apr-26-23 08:33AM
Apr-11-23 09:00AM
07:27AM
Mar-24-23 08:38AM
Mar-22-23 03:45AM
Mar-15-23 07:00AM
Mar-03-23 05:30AM
(The Wall Street Journal)
Feb-27-23 06:50AM
Feb-22-23 03:23AM
Feb-14-23 04:45PM
Feb-13-23 04:05PM
Feb-06-23 10:45PM
Feb-01-23 01:15PM
Jan-23-23 04:40PM
Jan-12-23 12:29PM
Jan-10-23 04:05PM
(GlobeNewswire) +15.26%
+31.31%
Jan-04-23 04:30PM
Dec-15-22 08:16AM
Inotiv, Inc. is a pharmaceutical development company, which engages in the provision of nonclinical and analytical drug discovery and development services primarily to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to academia and government clients. It operates under the Discovery and Safety Assessment (DSA) and Research Models and Services (RMS) segments. The DSA segment focuses on drug discovery and development services. The RMS segment includes commercial production and selling research models, diets, bedding, and bioproducts. The company was founded by Peter T. Kissinger in 1974 and is headquartered in West Lafayette, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Landman David Director Dec 19 '24 Buy 4.25 23,529 99,998 176,851 Dec 23 09:47 PM Beattie John Gregory Chief Operating Officer Dec 10 '24 Buy 4.75 30,000 142,500 161,761 Dec 12 06:46 PM Brown Nigel Director Dec 10 '24 Buy 4.26 7,500 31,950 65,537 Dec 10 04:13 PM Harrington Michael J Director Dec 06 '24 Buy 3.98 10,000 39,822 37,500 Dec 10 08:34 AM Landman David Director Dec 06 '24 Buy 4.14 100,000 414,000 153,322 Dec 10 08:31 AM
Index -
P/E 29.64
EPS (ttm) 0.41
Insider Own 1.49%
Shs Outstand 494.33M
Perf Week 2.11%
Market Cap 5.99B
Forward P/E 13.31
EPS next Y 0.91
Insider Trans 1.39%
Shs Float 486.97M
Perf Month -8.33%
Income 205.00M
PEG 2.96
EPS next Q 0.15
Inst Own 98.03%
Short Float 3.21%
Perf Quarter -16.48%
Sales 4.45B
P/S 1.34
EPS this Y 2.89%
Inst Trans -0.24%
Short Ratio 3.56
Perf Half Y -13.56%
Book/sh 13.20
P/B 0.92
EPS next Y -0.61%
ROA 1.48%
Short Interest 15.63M
Perf Year -18.72%
Cash/sh 0.99
P/C 12.22
EPS next 5Y 10.00%
ROE 3.24%
52W Range 11.40 - 18.80
Perf YTD -18.72%
Dividend Est. -
P/FCF 15.75
EPS past 5Y -
ROI 1.89%
52W High -35.59%
Beta 1.41
Dividend TTM -
Quick Ratio 1.31
Sales past 5Y 9.00%
Gross Margin 42.68%
52W Low 6.23%
ATR (14) 0.42
Dividend Ex-Date -
Current Ratio 2.55
EPS Y/Y TTM 117.83%
Oper. Margin 5.68%
RSI (14) 45.06
Volatility 2.71% 3.72%
Employees 9800
Debt/Eq 0.67
Sales Y/Y TTM 1.92%
Profit Margin 4.60%
Recom 1.81
Target Price 18.08
Option/Short Yes / Yes
LT Debt/Eq 0.66
EPS Q/Q 132.88%
Payout -
Rel Volume 0.54
Prev Close 11.82
Sales Surprise -0.61%
EPS Surprise 6.21%
Sales Q/Q -3.56%
Earnings Nov 07 BMO
Avg Volume 4.39M
Price 12.11
SMA20 -0.44%
SMA50 -5.31%
SMA200 -15.90%
Trades
Volume 2,415,221
Change 2.45%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-09-24 Initiated
UBS
Buy
$18
Dec-02-24 Initiated
Leerink Partners
Market Perform
$14
Sep-19-24 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$17 → $15
Jan-05-24 Upgrade
Stifel
Hold → Buy
$13 → $20
Dec-19-23 Initiated
Jefferies
Buy
$17
Dec-15-23 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$16
Dec-07-23 Initiated
Exane BNP Paribas
Outperform
$18
Apr-20-23 Upgrade
Barclays
Equal Weight → Overweight
$14
Aug-18-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$37 → $22
Aug-16-22 Downgrade
JP Morgan
Overweight → Neutral
$28 → $24
Jul-21-22 Downgrade
Goldman
Buy → Sell
$32 → $19
Jul-12-22 Initiated
Piper Sandler
Neutral
$22
Nov-18-21 Initiated
Morgan Stanley
Overweight
$40
Oct-28-21 Downgrade
Stifel
Buy → Hold
$37 → $34
Aug-05-21 Resumed
Credit Suisse
Outperform
$38
Jun-15-21 Upgrade
Cleveland Research
Underperform → Neutral
May-11-21 Upgrade
Gabelli & Co
Hold → Buy
May-11-21 Upgrade
Barclays
Underweight → Equal Weight
$25 → $29
Apr-15-21 Initiated
Stifel
Buy
$37
Mar-22-21 Downgrade
Gabelli & Co
Buy → Hold
Show Previous Ratings
Dec-19-24 11:07AM
Dec-01-24 09:08AM
Nov-29-24 12:18PM
Nov-27-24 01:45PM
Nov-26-24 07:22AM
04:31AM
Loading…
04:31AM
Nov-25-24 08:45AM
08:00AM
Nov-24-24 11:33AM
Nov-23-24 07:23AM
Nov-21-24 10:46AM
Nov-20-24 08:53AM
Nov-18-24 02:52PM
Nov-15-24 11:30AM
Nov-14-24 03:15PM
01:39PM
Loading…
Nov-13-24 01:39PM
Nov-12-24 07:20PM
(The Wall Street Journal)
08:33AM
05:45AM
Nov-11-24 04:02PM
Nov-08-24 04:03AM
02:09AM
02:03AM
(Thomson Reuters StreetEvents)
Nov-07-24 04:30PM
03:28PM
12:41PM
09:30AM
08:52AM
07:35AM
06:27AM
07:38AM
Loading…
Nov-05-24 07:38AM
Nov-04-24 03:51PM
09:16AM
Nov-01-24 05:45AM
Oct-31-24 01:42PM
10:01AM
Oct-30-24 11:46AM
Oct-28-24 07:17PM
Oct-25-24 09:56AM
Oct-24-24 02:29PM
Oct-23-24 10:16AM
Oct-22-24 10:42AM
Oct-21-24 06:12PM
Oct-17-24 12:14PM
12:10PM
Oct-16-24 11:21AM
08:54AM
Oct-11-24 09:14AM
Oct-10-24 08:00AM
Oct-09-24 11:23AM
Oct-08-24 08:43PM
Oct-07-24 04:19PM
Sep-20-24 10:35AM
Sep-19-24 03:08PM
01:42PM
12:50PM
Sep-13-24 07:30AM
Aug-28-24 06:30AM
Aug-20-24 06:27AM
Aug-15-24 08:27AM
Aug-13-24 01:49PM
Aug-09-24 02:35AM
(Thomson Reuters StreetEvents)
Aug-08-24 03:45PM
09:30AM
07:35AM
06:28AM
Aug-06-24 01:00PM
Aug-05-24 09:16AM
Aug-01-24 03:14PM
10:01AM
Jul-30-24 08:27AM
Jul-25-24 01:18PM
Jul-22-24 02:42PM
10:18AM
Jul-18-24 08:00AM
Jul-15-24 03:20PM
Jul-12-24 12:04PM
Jul-10-24 03:22PM
01:23PM
Jul-09-24 08:30AM
08:28AM
Jul-08-24 02:09PM
Jun-27-24 04:12PM
(Investor's Business Daily) -20.59%
06:27AM
Jun-07-24 12:00PM
Jun-06-24 08:00AM
May-28-24 07:30PM
06:27AM
May-24-24 02:39AM
May-23-24 04:03PM
May-21-24 08:00AM
May-13-24 09:17AM
May-09-24 08:54PM
11:33AM
10:26AM
09:44AM
07:43AM
(The Wall Street Journal)
03:05AM
May-08-24 04:04PM
(Investor's Business Daily) +24.93%
02:00PM
Elanco Animal Health, Inc. innovates, develops, manufactures, and markets products for pets and farm animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine. The Companion Animal Disease Prevention category engages in the broadest parasiticide portfolios in the companion animal sector based on indications, species and formulations, with products that protect pets from worms, fleas and ticks. The Companion Animal Therapeutics category provides the details of a broad pain and osteoarthritis portfolio across species, modes of action, indications and disease stages. The Food Animal Future Protein & Health category includes vaccines, nutritional enzymes and animal-only antibiotics, serves the growing demand for protein and includes innovative products in poultry and aquaculture production, where demand for animal health products is outpacing overall industry growth. It also focuses on developing functional nutritional health products that promote food animal health, including enzymes, probiotics and prebiotics. The Food Animal Ruminants & Swine category develops animal food products used in ruminant and swine production. The company was founded in 1954 and is headquartered in Greenfield, IN.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Harrington Michael J Director Aug 22 '24 Buy 14.85 3,500 51,974 81,094 Aug 26 05:05 PM Simmons Jeffrey N PRESIDENT, CEO AND DIRECTOR Aug 12 '24 Buy 13.01 100,000 1,300,610 145,000 Aug 13 09:04 AM DOYLE WILLIAM F Director May 21 '24 Buy 16.98 15,000 254,700 76,330 May 23 04:33 PM DOYLE WILLIAM F Director Mar 08 '24 Buy 16.30 15,000 244,500 61,330 Mar 12 04:32 PM Harrington Michael J Director Mar 08 '24 Buy 16.29 3,100 50,494 77,594 Mar 12 04:30 PM HOOVER R DAVID Director Mar 06 '24 Buy 16.14 20,000 322,808 185,000 Mar 08 05:09 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite